Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.
about
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerGaleterone for the treatment of advanced prostate cancer: the evidence to dateA sting in the tail: the N-terminal domain of the androgen receptor as a drug targetTherapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerNovel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate CancerEmerging data on androgen receptor splice variants in prostate cancerAndrogen receptor splice variants and prostate cancer: From bench to bedside.Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells.Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer.Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?Precision medicine for advanced prostate cancer.Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to AntiandrogensGaleterone and VNPT55 disrupt Mnk-eIF4E to inhibit prostate cancer cell migration and invasion.Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.Androgen receptor variation affects prostate cancer progression and drug resistance.Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives.Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in miceIdentification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole CarbamateAndrogen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancerClinical relevance of androgen receptor alterations in prostate cancer.Novel galeterone analogs act independently of AR and AR-V7 for the activation of the unfolded protein response and induction of apoptosis in the CWR22Rv1 prostate cancer cell model.Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.Role of androgen receptor splice variants in prostate cancer metastasis.The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival.Mycophenolate Mofetil induces c-Jun-N-terminal kinase expression in 22Rv1 cells: an impact on androgen receptor signaling.Thapsigargin induces apoptosis of prostate cancer through cofilin-1 and paxillin.
P2860
Q26739708-96B8D368-4107-4DF8-AB64-6B2398F574D4Q26739887-6FAA5F80-BE78-4B7B-8681-94BFEF535B01Q26747094-1F7BBFB9-24D4-46A0-837D-C89CE5FCCA0AQ26750620-4F83D335-A769-4BD4-84AC-BEF08E7CD4A4Q28067556-ADA2C36B-412B-4402-9B29-930FEB52C7B9Q28077830-662EB6F5-3C2B-454C-9BE7-D5CED6DD6B5EQ33567024-B6F34E41-C963-4E64-8A4F-ACD3F9E3F098Q33821011-3F451F41-475A-48F3-BFFC-D718B8C8F578Q36398998-B03A5B17-80F6-4CA9-BF13-316B12367933Q36880048-F4E9EFEF-1F2E-43A0-A0F0-BF134A22FFCBQ37013311-89E531F1-7DE7-48E6-A306-A2C2EEE4F13EQ37114034-DF80B8C3-9B33-4BFC-8E01-F7360D623E92Q38708121-79FB9131-2F74-493F-8C16-F68A80E59266Q38711529-49F17192-B425-4267-A53D-F6241FAF10C1Q38746805-D50D5305-0612-41BA-893D-7A452BE5FAECQ38775459-8FADE407-6957-401B-B024-3657E058C6D5Q38797560-04CE0E44-5247-4E93-88A1-45E730028440Q38835693-5AFE6E7B-EFD0-4F41-B4E9-4888EE8DC493Q38852008-3CE1B247-854D-4D22-A192-0FECF6A0EB7EQ38977288-07E6CDB5-FB09-4037-8986-11C7812219E9Q39285589-C81C0CB7-E26A-400F-BC5C-CDED4D1AC6AFQ40355149-8D6D88EA-608F-4291-AA6A-D31D3475307AQ41592725-02731D55-49A9-496B-A047-A78DE8C4BF49Q42123839-2731526D-28A1-4BB2-A73E-5FE69C2DA2E2Q42188589-D3FF05BE-6100-4999-83DC-25D01C082D8EQ42377108-BAC22FE8-B10E-4BE8-BA4A-629DE0BA165EQ47104372-F5836147-00A1-498C-96AD-0C2F447EA9B4Q48103666-7507154A-408C-44DB-A589-D42EDFE9C8F4Q50925353-EEF199EA-5E29-4D54-93E4-24AD0F95476CQ53749556-B25A75D0-AA51-439F-89E6-235CB2ED8B92Q55129906-39440E70-E5E4-4EF0-81C3-B78A20490025Q55375334-9F721AAE-29BE-4F9F-B55B-B6D1D4CB4062Q55646216-EB9C5493-4EBA-42F3-8AB8-A69EEC3F942B
P2860
Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Galeterone and VNPT55 induce p ...... ate cancer xenografts in vivo.
@ast
Galeterone and VNPT55 induce p ...... ate cancer xenografts in vivo.
@en
type
label
Galeterone and VNPT55 induce p ...... ate cancer xenografts in vivo.
@ast
Galeterone and VNPT55 induce p ...... ate cancer xenografts in vivo.
@en
prefLabel
Galeterone and VNPT55 induce p ...... ate cancer xenografts in vivo.
@ast
Galeterone and VNPT55 induce p ...... ate cancer xenografts in vivo.
@en
P2093
P2860
P356
P1433
P1476
Galeterone and VNPT55 induce p ...... tate cancer xenografts in vivo
@en
P2093
Andrew K Kwegyir-Afful
Puranik Purushottamachar
Senthilmurugan Ramalingam
Vidya P Ramamurthy
P2860
P304
27440-27460
P356
10.18632/ONCOTARGET.4578
P407
P577
2015-09-01T00:00:00Z